Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Dengvaxia in Healthy Malaysian Children
NCT01254422Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2010
- Primary completion
- Sep 2012
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever, dengue hemorrhagic fever (DHF), sponsored by Sanofi. Started Dec 2010; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue feverdengue hemorrhagic fever (DHF)
Beyond the preview
Go deeper on NCT01254422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254422.